Shares of Altimmune ALT fell 27.04% during market hours on Sep 14, even after the company announced positive top-line results from its 12-week phase I study. The study evaluated pemvidutide in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Altimmune, Inc. ALT announced positive topline results from its interim analysis of the MOMENTUM phase II obesity study on lead pipeline candidate pemvidutide. The company’s stock plunged about 55% on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results